Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NRIX 
Nurix Therapeutics Inc (NRIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: NRIX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $30.33
1 Year Target Price $30.33
| 10 | Strong Buy |
| 6 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.54% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 968.61M USD | Price to earnings Ratio - | 1Y Target Price 30.33 |
Price to earnings Ratio - | 1Y Target Price 30.33 | ||
Volume (30-day avg) 18 | Beta 2.16 | 52 Weeks Range 8.18 - 29.56 | Updated Date 07/11/2025 |
52 Weeks Range 8.18 - 29.56 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.6 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-09 | When Before Market | Estimate -0.714 | Actual -0.52 |
Profitability
Profit Margin - | Operating Margin (TTM) -340.67% |
Management Effectiveness
Return on Assets (TTM) -31.08% | Return on Equity (TTM) -64.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 534763327 | Price to Sales(TTM) 17.17 |
Enterprise Value 534763327 | Price to Sales(TTM) 17.17 | ||
Enterprise Value to Revenue 6.46 | Enterprise Value to EBITDA -3.35 | Shares Outstanding 76449400 | Shares Floating 57748462 |
Shares Outstanding 76449400 | Shares Floating 57748462 | ||
Percent Insiders 1.41 | Percent Institutions 111.85 |
Upturn AI SWOT
Nurix Therapeutics Inc
Company Overview
History and Background
Nurix Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule therapies targeting cellular protein control to treat cancer and other diseases. Founded in 2009, it has progressed from basic research to clinical-stage programs.
Core Business Areas
- Protein Modulation Therapies: Development of small molecule therapies that modulate cellular protein levels, primarily focusing on E3 ligases.
- Oncology: Development of therapies for various cancers, including hematological malignancies and solid tumors.
- Immuno-oncology: Development of therapies that enhance the body's immune system to fight cancer.
Leadership and Structure
The company is led by a management team with expertise in drug discovery, development, and commercialization. The organizational structure includes research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- DeTIL-0252: An orally bioavailable CBL-B inhibitor in Phase 1 for advanced solid tumors. Market share data is unavailable as it is in early clinical stages. Competitors include companies developing similar CBL-B inhibitors, if any, and standard of care for various solid tumors.
- NX-2127: An orally bioavailable BTK degrader in Phase 1 for relapsed/refractory B-cell malignancies. Market share data is unavailable as it is in early clinical stages. Competitors include companies developing BTK inhibitors and other therapies for B-cell malignancies, like Imbruvica (ibrutinib) from AbbVie and BeiGene.
- NX-1607: A targeted therapy to inhibit casitas B-lineage lymphoma-b (CBL-B), an E3 ubiquitin ligase. Market share data is unavailable as it is in early clinical stages. Competitors include companies developing similar CBL-B inhibitors, if any, and standard of care for various solid tumors.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. The immuno-oncology market is rapidly growing, driven by the success of checkpoint inhibitors and other immunotherapies.
Positioning
Nurix Therapeutics is positioned as an innovative player in the protein modulation space, targeting E3 ligases for therapeutic intervention. Its competitive advantage lies in its proprietary DELigase platform and expertise in protein degradation.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars. Nurix is positioned to capture a portion of this TAM with its novel protein modulation therapies, especially as the company develops advanced targeted drugs for oncology. Early estimation is 10-20 Billion USD
Upturn SWOT Analysis
Strengths
- Proprietary DELigase platform for E3 ligase modulation
- Experienced management team
- Strong intellectual property portfolio
- Focus on innovative protein degradation approaches
Weaknesses
- Early-stage clinical pipeline
- High R&D expenses
- Dependence on successful clinical trial outcomes
- Limited commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new therapeutic areas
- Positive clinical trial results
- Advancements in protein degradation technology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- ARVN
- KYMR
- CRBU
Competitive Landscape
Nurix Therapeutics competes with other biopharmaceutical companies developing novel therapies for cancer and other diseases. It differentiates itself through its focus on protein modulation and E3 ligase targeting. The company is early stage, therefore market share is negligible.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancement of preclinical programs and initiation of clinical trials. Revenue is limited as of now.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of its pipeline products. Analyst estimates vary based on clinical trial progress.
Recent Initiatives: Recent initiatives include advancing clinical trials for NX-2127 and DeTIL-0252, expanding its DELigase platform, and forging strategic partnerships.
Summary
Nurix Therapeutics is an early-stage biopharmaceutical company pioneering protein modulation therapies, particularly targeting E3 ligases for cancer treatment. Its proprietary DELigase platform positions it for innovation, but the company faces risks associated with clinical trials and competition. Successful clinical trial outcomes and strategic partnerships are key to future growth. Due to the early stage of the company, its current financial data doesn't accurately reflect the long term potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Nurix Therapeutics Investor Relations
- SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Please consult with a qualified financial advisor before making any investment decisions. Market share estimates for this novel targeted area are highly speculative given the early-stage nature of NRIX.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nurix Therapeutics Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2020-07-24 | CEO, President & Director Dr. Arthur T. Sands M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 286 | Website https://www.nurixtx.com |
Full time employees 286 | Website https://www.nurixtx.com | ||
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.